Do analysts rate LABT or KTTA?

Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 512.24%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, LABT or KTTA?

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lakewood-Amedex Biotherapeutics N/A N/A -$3.85M -$4.75 N/A Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A

Is LABT or KTTA more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lakewood-Amedex Biotherapeutics N/A N/A N/A Pasithea Therapeutics N/A -49.49% -46.81%

Do analysts recommend NCEL or LABT?

NLS Pharmaceutics currently has a consensus price target of $23.00, indicating a potential upside of 674.41%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, equities analysts plainly believe NLS Pharmaceutics is more favorable than Lakewood-Amedex Biotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, NCEL or LABT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Lakewood-Amedex Biotherapeutics N/A N/A -$3.85M -$4.75 N/A

Is NCEL or LABT more profitable?

Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Lakewood-Amedex Biotherapeutics N/A N/A N/A

Does the media prefer NCEL or LABT?

In the previous week, Lakewood-Amedex Biotherapeutics had 7 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 9 mentions for Lakewood-Amedex Biotherapeutics and 2 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.91 beat Lakewood-Amedex Biotherapeutics' score of 0.25 indicating that NLS Pharmaceutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lakewood-Amedex Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BCDA or LABT?

BioCardia presently has a consensus price target of $25.00, suggesting a potential upside of 2,327.18%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Lakewood-Amedex Biotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BCDA or LABT more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -569.36% -183.15% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Does the media prefer BCDA or LABT?

In the previous week, Lakewood-Amedex Biotherapeutics had 5 more articles in the media than BioCardia. MarketBeat recorded 9 mentions for Lakewood-Amedex Biotherapeutics and 4 mentions for BioCardia. BioCardia's average media sentiment score of 0.96 beat Lakewood-Amedex Biotherapeutics' score of 0.25 indicating that BioCardia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lakewood-Amedex Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CMMB or LABT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, CMMB or LABT?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.13 N/A Lakewood-Amedex Biotherapeutics N/A N/A -$3.85M -$4.75 N/A

Is CMMB or LABT more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -92.14% -82.05% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Do analysts recommend APLT or LABT?

Applied Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Applied Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is APLT or LABT more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Lakewood-Amedex Biotherapeutics (LABT) Competitors

$0.99 -0.16 (-13.93%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$0.99 +0.00 (+0.02%)

As of 09/29/2026 07:57 PM Eastern

Compare

LABT vs. KTTA, NCEL, BCDA, CMMB, and APLT

Should you buy Lakewood-Amedex Biotherapeutics stock or one of its competitors? Lakewood-Amedex Biotherapeutics's main competitors and comparable companies include Pasithea Therapeutics (KTTA), NLS Pharmaceutics (NCEL), BioCardia (BCDA), Chemomab Therapeutics (CMMB), and Applied Therapeutics (APLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lakewood-Amedex Biotherapeutics compare to Pasithea Therapeutics?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
Pasithea Therapeutics	N/A	-49.49%	-46.81%

23.9% of Pasithea Therapeutics shares are held by institutional investors. 5.4% of Lakewood-Amedex Biotherapeutics shares are held by insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 8 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 9 mentions for Lakewood-Amedex Biotherapeutics and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.82 beat Lakewood-Amedex Biotherapeutics' score of 0.25 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lakewood-Amedex Biotherapeutics	Neutral
Pasithea Therapeutics	Very Positive

Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 512.24%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lakewood-Amedex Biotherapeutics and Pasithea Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 7 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 9 mentions for Lakewood-Amedex Biotherapeutics and 2 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.91 beat Lakewood-Amedex Biotherapeutics' score of 0.25 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakewood-Amedex Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

NLS Pharmaceutics currently has a consensus price target of $23.00, indicating a potential upside of 674.41%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, equities analysts plainly believe NLS Pharmaceutics is more favorable than Lakewood-Amedex Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

Summary

NLS Pharmaceutics beats Lakewood-Amedex Biotherapeutics on 4 of the 6 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to BioCardia?

BioCardia (NASDAQ:BCDA) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 5 more articles in the media than BioCardia. MarketBeat recorded 9 mentions for Lakewood-Amedex Biotherapeutics and 4 mentions for BioCardia. BioCardia's average media sentiment score of 0.96 beat Lakewood-Amedex Biotherapeutics' score of 0.25 indicating that BioCardia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakewood-Amedex Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

20.6% of BioCardia shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioCardia presently has a consensus price target of $25.00, suggesting a potential upside of 2,327.18%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Lakewood-Amedex Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lakewood-Amedex Biotherapeutics has lower revenue, but higher earnings than BioCardia. BioCardia is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	259.90	-$8.23M	-$0.64	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A

Summary

BioCardia beats Lakewood-Amedex Biotherapeutics on 8 of the 13 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-92.14%	-82.05%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

46.1% of Chemomab Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 8 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 9 mentions for Lakewood-Amedex Biotherapeutics and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.82 beat Lakewood-Amedex Biotherapeutics' score of 0.25 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
Lakewood-Amedex Biotherapeutics	Neutral

Summary

Chemomab Therapeutics and Lakewood-Amedex Biotherapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Lakewood-Amedex Biotherapeutics has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

Applied Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Applied Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

98.3% of Applied Therapeutics shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Lakewood-Amedex Biotherapeutics had 8 more articles in the media than Applied Therapeutics. MarketBeat recorded 9 mentions for Lakewood-Amedex Biotherapeutics and 1 mentions for Applied Therapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.25 beat Applied Therapeutics' score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Applied Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakewood-Amedex Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lakewood-Amedex Biotherapeutics beats Applied Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Lakewood-Amedex Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LABT vs. The Competition

Export

Metric	Lakewood-Amedex Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.73M	$3.96B	$7.34B	$13.05B
Dividend Yield	N/A	3.63%	2.52%	14.18%
P/E Ratio	-0.21	13.66	273.79	25.68
Price / Sales	N/A	1,346.82	626.32	85.12
Price / Cash	N/A	121.91	80.06	52.35
Price / Book	N/A	15.28	10.44	6.34
Net Income	-$3.85M	-$22.71M	$3.50B	$360.56M
7 Day Performance	-44.39%	-2.05%	-1.41%	-1.59%
1 Month Performance	-56.97%	-8.36%	-4.17%	-4.08%
1 Year Performance	N/A	26.25%	12.60%	3.79%

Lakewood-Amedex Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LABT Lakewood-Amedex Biotherapeutics	0.7929 of 5 stars	$0.99 -13.9%	N/A	N/A	$2.73M	N/A	N/A	5	Gap Down
KTTA Pasithea Therapeutics	3.7983 of 5 stars	$0.50 -2.8%	$3.00 +501.0%	-31.0%	$17.17M	N/A	N/A	5	Positive News
NCEL NLS Pharmaceutics	2.8017 of 5 stars	$2.95 +2.1%	$23.00 +679.7%	-87.9%	$16.69M	N/A	N/A	6	Gap Down
BCDA BioCardia	3.8557 of 5 stars	$1.05 -1.9%	$25.00 +2,281.0%	-26.4%	$16.20M	$60K	N/A	21
CMMB Chemomab Therapeutics	1.4928 of 5 stars	$2.16 -1.8%	N/A	-39.2%	$15.94M	N/A	N/A	12	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LABT) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakewood-Amedex Biotherapeutics (LABT) Competitors

LABT vs. KTTA, NCEL, BCDA, CMMB, and APLT

How does Lakewood-Amedex Biotherapeutics compare to Pasithea Therapeutics?

Summary

How does Lakewood-Amedex Biotherapeutics compare to NLS Pharmaceutics?

Summary

How does Lakewood-Amedex Biotherapeutics compare to BioCardia?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Chemomab Therapeutics?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Applied Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LABT vs. The Competition

Lakewood-Amedex Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakewood-Amedex Biotherapeutics (LABT) Competitors

LABT vs. KTTA, NCEL, BCDA, CMMB, and APLT

How does Lakewood-Amedex Biotherapeutics compare to Pasithea Therapeutics?

Is LABT or KTTA more profitable?

Do insiders & institutionals believe in LABT or KTTA?

Which has stronger valuation & earnings, LABT or KTTA?

Does the media prefer LABT or KTTA?

Do analysts rate LABT or KTTA?

Summary

How does Lakewood-Amedex Biotherapeutics compare to NLS Pharmaceutics?

Which has better earnings and valuation, NCEL or LABT?

Does the media prefer NCEL or LABT?

Do analysts recommend NCEL or LABT?

Is NCEL or LABT more profitable?

Summary

How does Lakewood-Amedex Biotherapeutics compare to BioCardia?

Is BCDA or LABT more profitable?

Does the media prefer BCDA or LABT?

Do institutionals and insiders hold more shares of BCDA or LABT?

Do analysts prefer BCDA or LABT?

Which has better valuation & earnings, BCDA or LABT?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Chemomab Therapeutics?

Do analysts prefer CMMB or LABT?

Is CMMB or LABT more profitable?

Do institutionals & insiders believe in CMMB or LABT?

Which has higher valuation & earnings, CMMB or LABT?

Does the media favor CMMB or LABT?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Applied Therapeutics?

Which has preferable earnings & valuation, APLT or LABT?

Is APLT or LABT more profitable?

Do analysts recommend APLT or LABT?

Do institutionals and insiders believe in APLT or LABT?

Does the media prefer APLT or LABT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LABT vs. The Competition

Lakewood-Amedex Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools